Factor V Leiden mutation in patients with breast cancer with a central venous catheter: Risk of deep vein thrombosis

Supportive Cancer Therapy

Volumn 3, Issue 2, 2006, Pages 98-102

  Curigliano, Giuseppe ^a   Mandalà, Mario ^a   Sbanotto, Alberto ^a   Colleoni, Marco ^a   Ferretti, Gianluigi ^a   Bucciarelli, Paolo ^b   Peruzzotti, Giulia ^a   De Braud, Filippo ^a   De Pas, Tommaso ^a   Spitaleri, Gianluca ^a   Pietri, E ^a   Orsi, Franco ^a   Banfi, Maria G ^a   Goldhirsch, Aron ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Chemotherapy; Thrombophilic mutation; Vascular access devices; Venous thromboembolism

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; FLUOROURACIL; PROTHROMBIN;

ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER STAGING; CENTRAL VENOUS CATHETER; CLINICAL ARTICLE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; FEMALE; HUMAN; INFORMED CONSENT; LOGISTIC REGRESSION ANALYSIS; METASTASIS; MUTATION; PROGNOSIS;

EID: 33646016004     PISSN: 15432912     EISSN: None     Source Type: Journal    
DOI: 10.3816/SCT.2006.n.005     Document Type: Article

References (30)

1. Rickles FR, Levine M, Edwards RL. Hemostatic alterations in cancer patients. Cancer Metastasis Rev 1992; 11:237-248.
2. Green KB, Silverstein RL. Hypercoagulability in cancer. Hematol Oncol Clin North Am 1996; 10:499-530.
3. Folkman J. Tumor angiogenesis and tissue factor. Nat Med 1996; 2:167-168.
4. Dvorak HF. Abnormalities of hemostasis in malignant disease. In: Colman RW, Hirsh J, Marder VJ, et al, eds. Hemostasis and Thombosis: Basic Principles and Clinical Practice. Philadelphia: Lippincott Williams & Wilkins, 1994:25-50.
5. Lee Agnes YY, Levine M. The thrombophilic state induced by therapeutic agents in the cancer patient. Semin Thromb Hemost 1999; 25:137-145.
6. Piccioli A, Prandoni P, Ewenstein BM, et al. Cancer and venous thromboembolism. Am Heart J 1996; 132:850-855.
7. Levine MN, Lee AY. Treatment of venous thrombosis in cancer patients. Acta Haematol 2001; 106:81-87.
8. Freytes CO. Indications and complications of intravenous devices for chemotherapy. Curr Opin Oncol 2000; 12:303-307.
9. Prandoni P, Bernardi E. Upper extremity deep vein thrombosis. Curr Opin Pulmon Med 1999; 5:222-226.
10. Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis. N Engl J Med 2001; 344:1222-1231.
11. Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet 1999; 353:1167-1173.
12. Mandala M, Ferretti G, Cremonesi M, et al. Venous thromboembolism and cancer: new issues for an old topic. Crit Rev Oncol Hematol 2003; 48:65-80.
13. Mannucci PM, Poller L. Venous thrombosis and anticoagulant therapy. Br J Haematol 2001; 114:258-270.
14. Mannucci PM. Genetic hypercoagulability: prevention suggests testing family members. Blood 2001; 98:21-22.
15. Mandala M, Curigliano G, Bucciarelli P, et al. Factor V Leiden and G20210A prothrombin mutation and the risk of subclavian vein thrombosis in patients with breast cancer and a central venous catheter. Ann Oncol 2004; 15:590-593.
16. Orlando L, Colleoni M, Nole F, et al. Incidence of venous thromboembolism in breast cancer patients during chemotherapy with vinorelbine, cisplatin, 5-fluorouracil as continuous infusion (ViFuP regimen): is prophylaxis required? Ann Oncol 2000; 11:117-118.
17. Francis CW, Felcher AH, White J, et al. Thrombin activity associated with indwelling central venous catheters. Thromb Haemost 1997; 77:48-52.
18. Feffer SE, Carmosino LS, Fox RL. Acquired protein C deficiency in patients with breast cancer receiving cyclophosphamide, methotrexate, and 5-fluorouracil. Cancer 1989; 63:1303-1307.
19. Taher A, Shamsseddine A, Saghir N, et al. Acquired protein C deficiency following cisplatinum-navelbine administration for locally advanced breast cancer. Case report. Eur J Gynaecol Oncol 1999; 20:323-324.
20. Fijnheer R, Paijmans B, Verdonck LF, et al. Factor V Leiden in central venous catheter-associated thrombosis. Br J Haematol 2002; 118:267-270.
21. Sifontes MT, Nuss R, Hunger SP, et al. The factor V Leiden mutation in children with cancer and thrombosis. Br J Haematol 1997; 96:484-489.
22. Rees D, Grimwade D, Langabeer S, et al. Influence of genetic predisposition to thrombosis on natural history of acute promyelocytic leukaemia. MRC Adult Leukaemia Working Party. Br J Haematol 1997; 96:490-492.
23. Mitchell LG, Andrew M, Hanna K, et al. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase: results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) Study. Cancer 2003; 97:508-516.
24. Geerts WH, Heit JA, Clagett GP et al. Prevention of venous thromboembolism. Chest 2001; 119:132S-175S.
25. Bern MM, Lokich JJ, Wallach SR, et al. Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomised prospective trial. Ann Intern Med 1990; 112:423-428.
26. Bona RD, Hickey AD, Wallace DM. Efficacy and safety of oral anticoagulation in patients with cancer. Thromb Haemost 1997; 8:137-140.
27. Reichardt P, Kretzschmar A, Biakhov M, et al. A phase III randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of daily low-molecular-weighr heparin (dalteparin sodium, fragmin) in preventing catheter-related complications (CRCs) in cancer patients with central venous catheters (CVCs). Proc Am Soc Clin Oncol 2002; 21:369a (Abstract #1474).
28. Vardy JL, Engelhardt K, Cox K, et al. Subcutaneous central venous access port devices (CV APDs) inserted by interventional radiologists in cancer patients. Proc Am Soc Clin Oncol 2002; 21:256b (Abstract #2843).
29. Masci G, Magagnoli M, Zucali PA, et al. Minidose warfarin prophylaxis for catheter-associated thrombosis in cancer patients: can it be safely associated with fluorouracil-based chemotherapy? J Clin Oncol 2003; 21:736-739.
30. Carr KM, Rabinowitz I. Physician compliance with warfarin prophylaxis for central venous catheters in patients with solid tumours. J Clin Oncol 2000; 18:3665-3667.